Review article: The long-term management of ulcerative colitis

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 4, 2004, Pages 97-101

  Hanauer, S B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; ENEMA; IMMUNOMODULATING AGENT; MERCAPTOPURINE; MESALAZINE; NICOTINE; OLSALAZINE; PLACEBO; PROBIOTIC AGENT; PURINE ANTAGONIST; SALAZOSULFAPYRIDINE;

ARTHRALGIA; CANCER PREVENTION; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CANCER; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESISTANCE; DYSPLASIA; HEADACHE; HUMAN; IMMUNOMODULATION; INDUCTION THERAPY; LONG TERM CARE; MAINTENANCE THERAPY; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; REMISSION; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SMOKING CESSATION; STEROID DEPENDENCE; STEROID THERAPY; THERAPY; TREATMENT DURATION; TREATMENT INTENSITY; ULCERATIVE COLITIS;

AMINOSALICYLIC ACIDS; COLITIS, ULCERATIVE; DRUG RESISTANCE; HUMANS; IMMUNOLOGIC FACTORS; LONG-TERM CARE; NICOTINE;

EID: 4844226052     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107(1): 3-11.
2. Fredd S. Standards for Approval of New Drugs for IBD. Inflamm Bowel Dis 1995; 1(4): 284-94.
3. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32(2): 174-8.
4. Kamm MA. Review article: maintenance of remission in ulcerative colitis. Aliment Pharmacol Ther 2002; 16(Suppl. 4): 21-4.
5. Ardizzone S, Petrillo M, Imbesi V, Cerutti R, Bollani S, Bianchi Porro G. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 1999; 13(3): 373-9.
6. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334(13): 841-8.
7. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002; 4: CD000544.
8. Gisbert JP, Gomollon F, Mate J, Pajares JM. Role of 5-amino-salicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 2002; 47(3): 471-88.
9. Mulder CJ, Tytgat GN, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1998; 95(6): 1449-53.
10. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996; 124(2): 204-11.
11. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92(2): 204-11.
12. Hanauer SB. Aminosalicylate therapy for ulcerative colitis. In: Bayless TM, Hanauer SB, eds. Advanced Therapy of Inflammatory Bowel Disease. Hamilton, Ont.: B.C. Decker Inc, 2001: 123-6.
13. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95(5): 1263-76.
14. d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized, double-blind study. Am J Gastroenterol 1997; 92(7): 1143-7.
15. Eaden J. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18(Suppl. 2): 15-21.
16. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18(Suppl. 2): 10-4.
17. Langholz E, Munkhom P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103: 1444-51.
18. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18(Suppl. 2): 1-5.
19. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999; 354(9179): 635-9.
20. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114(1): 39-43.
21. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91(9): 1711-4.
22. Actis GC, Bresso F, Astegiano M, et al. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther 2001; 15(9): 1307-11.
23. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94(6): 1587-92.
24. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4(5945): 627-30.
25. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis, Br Med J 1992; 305(6844): 20-2.
26. Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G, Molteni F. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997; 25(1): 330-3.
27. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50(4): 485-9.
28. Thomas GAJ, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995; 332(15): 988-92.
29. Miner PB Jr. Factors influencing the relapse of patients with inflammatory bowel disease. Am J Gastroenterol 1997; 92(12 Suppl.): 1S-4S.
30. Gelbmann CM. Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease - do we have reliable markers? Inflamm Bowel Dis 2000; 6(2): 123-31.